OncoLink at ASCO 1996: Sunday, May 19

photo of R. Judith Radzan, MD and Peter Cassileth, MD, Miami,Florida, USA

Photo (l to r): R. Judith Radzan, MD, Peter Cassileth, MD, Miami, Florida, USA

National Cancer Insitute Director's Address
New Discoveries in Treating Women's Cancer Reported at ASCO Meeting
Optimal Timing of Breast Cancer Surgery Within Menstrual Cycle
Phase I Study Results for Pegylated Megakaryocyte Growth And Development Factor, A New Platelet Growth Factor
Phase I Study Results for Thrombopoietin, A New Cytokine

Progression-Free Survival Not Tied to R-CHOP Dose Density

Sep 21, 2011 - There is no significant difference in progression-free survival for patients with indolent B-cell lymphoma treated with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone along with granulocyte colony-stimulating factor every three weeks or every two weeks, according to a study published online Sept. 19 in the Journal of Clinical Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More